Ignite Creation Date:
2025-12-24 @ 6:43 PM
Ignite Modification Date:
2025-12-29 @ 11:09 PM
Study NCT ID:
NCT03346057
Status:
COMPLETED
Last Update Posted:
2020-10-08
First Post:
2017-11-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-12-20
Start Date Type:
ACTUAL
Primary Completion Date:
2019-09-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-09-04
Completion Date Type:
ACTUAL
First Submit Date:
2017-11-15
First Submit QC Date:
None
Study First Post Date:
2017-11-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-08-24
Results First Submit QC Date:
None
Results First Post Date:
2020-10-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-05
Last Update Post Date:
2020-10-08
Last Update Post Date Type:
ACTUAL